Methods In this retrospective cohort study, 125 474 adults with overweight or obesity newly initiated treatment with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023, with a baseline body mass index of 27 or more, an available weight measurement within 60 days before initiation, and regular care in the year before initiation were identified using electronic health record data from a collective of US health care systems
Do not walk barefoot or wear shoes without socks
Its important to adjust dosage only under medical supervision
Patients should understand whether their chosen platform offers ongoing clinical assessment versus transactional prescription fulfillment
The moment you puncture that stopper, the clock starts ticking
A study by Newsome et al., designed to evaluate semaglutide as a potential treatment for Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), showed a dose dependent decrease in ALT levels, with maximal reductions occurring around week 28 and remaining stable thereafter [38]
